Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer

Wenjin Yin

Status: Enrolling

Conditions: Breast Cancer

Treatments: Drug: CDK4/6 inhibitor

Study type: Observational

Funder types: Other

Identifiers

NCT07180056

LY2025-108-B

Details and patient eligibility

About

To evaluate the efficacy and safety of adjuvant CDK4/6 inhibitors in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.

Enrollment: 229 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Aged ≥18 and older
• Patients with pathologically confirmed breast cancer without distant metastasis or local recurrence
• HR+/HER2-
• ECOG 0-3
• Subjects meeting current guideline recommendations and planning to receive adjuvant CDK4/6 inhibitors

Exclusion criteria

• During pregnancy or lactation
• Subjects that are unable to swallow tablets, or dysfunction of gastrointestinal absorption

Trial design

229 participants in 1 patient group

Adjuvant CDK4/6 inhibitor

Description:

CDK4/6 inhibitors are drugs that block cell division in cancer cells. They are used with hormonal therapy for hormone receptor-positive breast cancer and may improve survival.

Treatment:

Drug: CDK4/6 inhibitor